Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study

COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date, no treatment has yet demonstrated Strong efficacy in treating the infectious disease (COVID-19). Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high potential,due to higher local concentrations and minimal adverse effects. Type I interferons (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In existing preliminary studies, only patients receiving IFN type I modulators have a decrease in viral carriage and a rapid reversal. The purpose of this project is to assess in hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements of the addition of inhaled Interferon type I compared to the control arm .

NCT Number	NCT04469491
Lead Sponsor	Centre Hospitalier Universitaire, Amiens Collaborators: CH TOURCOING, CH ARROND DE MONTREUIL, CH SAINT-QUENTIN, Centre Hospitalier Intercommunal de Compiègne-Noyon, Abbeville Hospital Center, CH VALENCIENNES, Clinique Teissier, University Hospital, Toulouse, University Hospital, Angers, University Hospital, Caen, Nantes University Hospital
Conditions	COVID-19, INTERFERON, NEBULIZATION
Enrollment	74 participants
Start Date	2020-09-20
Primary Completion	2023-06-16 (estimated)
Study Completion	2025-12 (estimated)
Updated on ClinicalTrials.gov	2025-11-19